Core Viewpoint - The company has initiated a share buyback program, demonstrating confidence in its stock value and commitment to returning capital to shareholders [1] Summary by Categories Share Buyback Details - The company repurchased 850,000 shares, representing 0.05% of its total share capital [1] - The highest transaction price was 6.29 CNY per share, while the lowest was 6.24 CNY per share [1] - The total amount spent on the buyback was 5.3267 million CNY, excluding transaction fees [1] Compliance and Strategy - The buyback is in accordance with relevant laws and regulations [1] - The action aligns with the company's established buyback plan [1]

证券代码：002099 证券简称：海翔药业 公告编号：2025-035 浙江海翔药业股份有限公司 关于首次回购公司股份的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）于 2025 年 4 月 9 日召开 第七届董事会第十三次会议，审议通过了《关于回购股份方案的议案》，同意公 司使用自有/自筹资金以集中竞价交易方式回购部分公司股票（以下简称"本次 回购"），在未来适宜时机用于股权激励或者员工持股计划。本次回购资金总额 不低于人民币 15,000 万元（含），不超过人民币 30,000 万元（含），回购价格 不超过人民币 7.46 元/股（含）。本次回购的实施期限自董事会审议通过本回购 方案之日起 12 个月内。具体内容详见公司于 2025 年 4 月 10 日在《证券时报》 《证券日报》和巨潮资讯网（www.cninfo.com.cn）上披露的《关于回购股份方 案的公告》（公告编号：2025-005）。 一、首次回购公司股份的具体情况 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号— ...

Company Overview - Haisheng Pharmaceutical's latest stock price is 6.26 yuan, an increase of 0.04 yuan from the previous trading day [1] - The stock reached a high of 6.27 yuan and a low of 6.06 yuan during the trading session, with a trading volume of 188,012 hands and a transaction amount of 116 million yuan [1] Industry Information - The company operates in the chemical pharmaceutical industry, focusing on the research, development, production, and sales of pharmaceutical raw materials and intermediates [1] - Its product range includes treatments for various fields such as anti-infection, cardiovascular, and mental health [1] Shareholder and Market Data - As of July 31, 2025, the number of shareholders for Haisheng Pharmaceutical is 30,100, a decrease of 1,001 from the previous period [1] - The average number of circulating shares held per shareholder increased from 52,000 to 53,700 shares, with an average circulating market value of 335,100 yuan [1] - The number of shares held through the Shenzhen Stock Connect is 12.69 million, accounting for 0.78% of the circulating share capital [1] Capital Flow - On August 4, the net outflow of main funds was 13.89 million yuan, representing 0.14% of the circulating market value [1] - Over the past five days, the net inflow of main funds was 354,700 yuan [1]

证券代码：002099 证券简称：海翔药业 公告编号：2025-034 浙江海翔药业股份有限公司 关于为合并报表范围内子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，公司与招商银行股份有限公司台州分行重新签署《最高额不可撤销担 保书》，同意公司继续为金沣医药申请商业汇票、信用证、保函等各类融资提供 5,000 万元人民币连带保证责任。本次对外担保系原担保展期，未新增额度。 三、担保书的主要内容 1、担保金额：5,000 万元人民币。 2、担保方式：连带保证责任。 一、担保情况概述 浙江海翔药业股份有限公司（以下简称"公司"）分别于 2025 年 4 月 28 日 召开了第七届董事会第十四次会议,2025 年 5 月 21 日召开了 2024 年年度股东大 会，审议通过了《关于为合并报表范围内子公司提供担保额度的议案》，同意为 合并报表范围内子公司台州金沣医药化工有限公司（以下简称"金沣医药"）提 供不超过人民币 10,000 万元（或等值外币）担保额度。具体详见公司于 2025 年 4 月 29 日在《证券时报》《证券日报》和巨 ...

Group 1 - The core point of the article is that Haixiang Pharmaceutical announced on the evening of August 1 that as of July 31, 2025, the company has not yet started the implementation of the current share repurchase plan [2]

一、回购公司股份的进展情况 关于股份回购进展情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）于 2025 年 4 月 9 日召开 第七届董事会第十三次会议，审议通过了《关于回购股份方案的议案》，同意公 司使用自有/自筹资金以集中竞价交易方式回购部分公司股票（以下简称"本次 回购"），在未来适宜时机用于股权激励或者员工持股计划。本次回购资金总额 不低于人民币 15,000 万元（含），不超过人民币 30,000 万元（含），回购价格 不超过人民币 7.46 元/股（含）。本次回购的实施期限自董事会审议通过本回购 方案之日起 12 个月内。具体内容详见公司于 2025 年 4 月 10 日在《证券时报》 《证券日报》和巨潮资讯网（www.cninfo.com.cn）上披露的《关于回购股份方 案的公告》（公告编号：2025-005）。 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关 规定，公司应当在回购期间每个月的前三个交易日内披露截至上月末的回购进展 情况。现将公司截至上月末的回购股份 ...

金融界消息 截至2025年7月29日收盘，海翔药业（002099）报收于6.25元，上涨1.96%，换手率1.42%， 成交量22.87万手，成交金额1.42亿元。 海翔药业最新一期业绩显示，截至2025一季报，公司营业总收入4.86亿元、同比减少7.95%，归属净利 润922.99万元，同比减少71.68%，扣非净利润651.46万元，同比减少80.41%，流动比率1.322、速动比率 0.985、资产负债率32.30%。 天眼查商业履历信息显示，浙江海翔药业股份有限公司，成立于1998年，位于台州市，是一家以从事医 药制造业为主的企业。企业注册资本161871.5253万人民币，实缴资本161871.5253万人民币。公司法定 代表人为孙杨。 资金流向方面，今日主力资金净流入1597.98万元，占比成交额11.21%。其中，超大单净流入1268.23万 元、占成交额8.9%，大单净流入329.75万元、占成交额2.31%，中单净流出流出65.47万元、占成交额 0.46%，小单净流出1532.51万元、占成交额10.76%。 通过天眼查大数据分析，浙江海翔药业股份有限公司共对外投资了28家企业，参与招投标 ...

Group 1: Raw Material Development - The price of penicillin products has been declining but showed signs of recovery in Q2 2025, with an optimistic market outlook for sustained price recovery [1] - The global demand for clindamycin series remains stable, with Q1 sales showing a year-on-year increase and maintaining a good gross margin [1] - The company has diversified its raw material drug portfolio across various fields, including anti-infection, diabetes, dermatology, ophthalmology, and psychiatric medications, with products at different R&D stages [1] Group 2: CMO/CDMO Business Expansion - The company has seen good growth in existing collaborations with strategic clients, leading to a year-on-year increase in cooperation orders [2] - New projects are in the validation phase, with successful completion of validation for anti-infection products and ongoing global market registration changes [2] - The peptide platform is expanding its supply volume while actively seeking high-value new project collaborations to enhance revenue [2] Group 3: Formulation Business Strategy - Three formulation products have passed consistency evaluations, and one product has won a national procurement bid, with plans to expand market sales through collaborations rather than building a sales team [2] - The company aims to enrich its formulation product line and create an integrated industrial platform covering intermediates, raw materials, and formulations [2] - Ongoing collaborations with overseas formulation companies are being explored for opportunities in modified new drug development [2] Group 4: Innovation Drug Sector - The company currently does not engage in innovative drug R&D but provides CMO/CDMO services for clinical-stage innovative drugs and patented products for leading global and domestic pharmaceutical companies [2] - Investments in industry funds include projects related to HPV infection, liver cancer therapeutic vaccines, TCR-T cell therapy, and recombinant drugs [2] Group 5: Dye Market Dynamics - The company leads in the niche market of anthraquinone active blue dye products and has adjusted prices based on market conditions this year [2] - Continuous monitoring of market sales and price trends will guide timely adjustments to production plans, maintaining competitive advantages in the dye market [2]

Group 1 - Zhejiang Haixiang Pharmaceutical Co., Ltd. has received notification from its actual controller, Mr. Wang Yunfu, regarding the extension of stock pledge repurchase transactions conducted through CITIC Securities Co., Ltd. [1] - The stock pledge repurchase extension involves a total of 39.32% of the company's total share capital, with 2.89% of shares pledged for repurchase [1]. - As of the announcement date, Mr. Wang Yunfu, Mr. Wang Yangchao, and Zhejiang Donggang Industrial Co., Ltd. have a total of 644,828,587 pledged shares, accounting for 39.84% of the company's total share capital [2][3]. Group 2 - Mr. Wang Yunfu holds 118,800,000 shares, representing 7.34% of the total shares, with 46,710,000 shares pledged, which is 39.32% of his holdings [1]. - Mr. Wang Yangchao has pledged 2,046,000 shares, accounting for 0.13% of the total shares [2]. - Zhejiang Donggang Industrial Co., Ltd. has pledged 523,982,587 shares, which is 32.37% of its holdings [3].

| 股东名 | 是否为控 股股东或 第一大股 | 本 次 质 押 延 期 | | 占其所持 | 占 公 司 | 是否 | 是否 | 质 | 押 | 原 | 到 | 延 期 | 质 权 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 称 | | 股 份 数 | | 股份比例 | 总 股 本 | 为限 | 补充 | 起 | 始 | 期 | 购 | 购 回 | 人 | 质押用途 | | | 东及其一 | 量 | | | 比例 | 售股 | 质押 | 日 | | 回日 | | 日 | | | | | 致行动人 | | | | | | | | | | | | | | | | | | | | | | | | 2024 | | 2025 | 2026 | 中 信 证 券 | | | | | | 44,60 | | | | | 年 | 7 | 年 | 7 | 年 7 | | 个人资金 | | 王云富 | 是 | | 0,000 | 37.54% | 2.76% | 否 | 否 | ...